Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma.
Bolomsky A, Ceribelli M, Scheich S, Rinaldi K, Huang DW, Chakraborty P, Pham L, Wright GW, Hsiao T, Morris V, Choi J, Phelan JD, Holewinski RJ, Andresson T, Wisniewski J, Riley D, Pittaluga S, Hill E, Thomas CJ, Muppidi J, Young RM. Bolomsky A, et al. Among authors: scheich s. Cancer Cell. 2024 Jul 8;42(7):1185-1201.e14. doi: 10.1016/j.ccell.2024.05.026. Epub 2024 Jun 20. Cancer Cell. 2024. PMID: 38906156
Molecular targets of glucocorticoids that elucidate their therapeutic efficacy in aggressive lymphomas.
Choi J, Ceribelli M, Phelan JD, Häupl B, Huang DW, Wright GW, Hsiao T, Morris V, Ciccarese F, Wang B, Corcoran S, Scheich S, Yu X, Xu W, Yang Y, Zhao H, Zhou J, Zhang G, Muppidi J, Inghirami GG, Oellerich T, Wilson WH, Thomas CJ, Staudt LM. Choi J, et al. Among authors: scheich s. Cancer Cell. 2024 May 13;42(5):833-849.e12. doi: 10.1016/j.ccell.2024.04.007. Epub 2024 May 2. Cancer Cell. 2024. PMID: 38701792
Molecular Determinants of Sensitivity to Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma.
Corcoran SR, Phelan JD, Choi J, Shevchenko G, Fenner RE, Yu X, Scheich S, Hsiao T, Morris VM, Papachristou EK, Kishore K, D'Santos CS, Ji Y, Pittaluga S, Wright GW, Urlaub H, Pan KT, Oellerich T, Muppidi J, Hodson DJ, Staudt LM. Corcoran SR, et al. Among authors: scheich s. Cancer Discov. 2024 Sep 4;14(9):1653-1674. doi: 10.1158/2159-8290.CD-23-0802. Cancer Discov. 2024. PMID: 38683128
Response to Bruton's tyrosine kinase inhibitors in aggressive lymphomas linked to chronic selective autophagy.
Phelan JD, Scheich S, Choi J, Wright GW, Häupl B, Young RM, Rieke SA, Pape M, Ji Y, Urlaub H, Bolomsky A, Doebele C, Zindel A, Wotapek T, Kasbekar M, Collinge B, Huang DW, Coulibaly ZA, Morris VM, Zhuang X, Enssle JC, Yu X, Xu W, Yang Y, Zhao H, Wang Z, Tran AD, Shoemaker CJ, Shevchenko G, Hodson DJ, Shaffer AL 3rd, Staudt LM, Oellerich T. Phelan JD, et al. Among authors: scheich s. Cancer Cell. 2024 Feb 12;42(2):238-252.e9. doi: 10.1016/j.ccell.2023.12.019. Epub 2024 Jan 11. Cancer Cell. 2024. PMID: 38215749
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience.
Enßle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, Mikesch JH, Krause S, Sauer T, Hanoun M, Reinhardt HC, Kraus S, Kaufmann M, Hänel M, Fransecky L, Burchert A, Neubauer A, Crysandt M, Jost E, Niemann D, Schäfer-Eckart K, Held G, Kaiser U, Wass M, Schaich M, Müller-Tidow C, Platzbecker U, Baldus CD, Bornhäuser M, Röllig C, Serve H; Study Alliance Leukemia (SAL); Steffen B. Enßle JC, et al. Among authors: scheich s. Br J Cancer. 2023 Oct;129(7):1126-1133. doi: 10.1038/s41416-023-02362-3. Epub 2023 Aug 4. Br J Cancer. 2023. PMID: 37542108 Free PMC article.
Targeting N-linked Glycosylation for the Therapy of Aggressive Lymphomas.
Scheich S, Chen J, Liu J, Schnütgen F, Enssle JC, Ceribelli M, Thomas CJ, Choi J, Morris V, Hsiao T, Nguyen H, Wang B, Bolomsky A, Phelan JD, Corcoran S, Urlaub H, Young RM, Häupl B, Wright GW, Huang DW, Ji Y, Yu X, Xu W, Yang Y, Zhao H, Muppidi J, Pan KT, Oellerich T, Staudt LM. Scheich S, et al. Cancer Discov. 2023 Aug 4;13(8):1862-1883. doi: 10.1158/2159-8290.CD-22-1401. Cancer Discov. 2023. PMID: 37141112 Free PMC article.
SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma.
Wilke AC, Doebele C, Zindel A, Lee KS, Rieke SA, Ceribelli M, Comoglio F, Phelan JD, Wang JQ, Pikman Y, Jahn D, Häupl B, Schneider C, Scheich S, Tosto FA, Bohnenberger H, Stauder P, Schnütgen F, Slabicki M, Coulibaly ZA, Wolf S, Bojarczuk K, Chapuy B, Brandts CH, Stroebel P, Lewis CA, Engelke M, Xu X, Kim H, Dang TH, Schmitz R, Hodson DJ, Stegmaier K, Urlaub H, Serve H, Schmitt CA, Kreuz F, Knittel G, Rabinowitz JD, Reinhardt HC, Vander Heiden MG, Thomas C, Staudt LM, Zenz T, Oellerich T. Wilke AC, et al. Among authors: scheich s. Blood. 2022 Jan 27;139(4):538-553. doi: 10.1182/blood.2021012081. Blood. 2022. PMID: 34624079 Free PMC article.
27 results